Breast Tumour Size Measurement by Field Cycling Imaging

NCT07492043 | Not Yet Recruiting

• 2 other identifiers: 2-082-2525/NW/0355
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is: Can FCI accurately estimate DCIS lesion size compared with histology results? Participants will have a standard MRI scan and an FCI scan before undergoing surgery to remove the tumour.

Conditions

Breast Cancer; Ductal Carcinoma In Situ

Keywords

Field-Cycling Imaging; FCI; DCIS; Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).

  Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.

  Baseline

Secondary Outcomes (1)

• Comparison of DCIS lesion measurements using FCI and 3T MRI.

  Baseline

Study Arms (1)

Breast Cancer

Participants with breast cancer of ductal carcinoma in-situ (DCIS) who are due to undergo surgical treatment.

Other: Field-Cycling Imaging research scan; Other: 3T MRI research scan

Interventions

Field-Cycling Imaging research scan OTHER

Baseline FCI scan

Breast Cancer

3T MRI research scan OTHER

Baseline MRI scan

Breast Cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female patients from the Breast Unit of Aberdeen Royal Infirmary diagnosed with DCIS on clinical imaging with a breast tumour of at least 1 cm on imaging undergoing surgery.

You may qualify if:

• Females ≥ 18 years old.
• Subjects diagnosed with DCIS on initial biopsy.
• Lesion size \>1 cm on imaging.
• Subjects undergoing surgery as part of their treatment.
• Able to fit comfortably in the scanners.
• Able to understand written and spoken English.

You may not qualify if:

• Subjects undergoing chemotherapy or hormonal therapy.
• Individuals unable to give informed consent.
• Contra-indications to MRI scanning such as implantable cardiac devices.
• Known allergy to contrast agent.

Sponsors & Collaborators

• University of Aberdeen: lead
• NHS Grampian: collaborator

Study Sites (1)

University of Aberdeen

Aberdeen, United Kingdom

Location

Related Publications (1)

• Mallikourti V, Ross PJ, Maier O, Hanna K, Husain E, Davies GR, Lurie DJ, Lip G, Lahrech H, Masannat Y, Broche LM. Field cycling imaging to characterise breast cancer at low and ultra-low magnetic fields below 0.2 T. Commun Med (Lond). 2024 Oct 30;4(1):221. doi: 10.1038/s43856-024-00644-2.

  PMID: 39478081 BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Breast Carcinoma In Situ; Carcinoma in Situ; Neoplasms, Ductal, Lobular, and Medullary

Study Officials

• Vasiliki Mallikourti, PhD

  University of Aberdeen

  STUDY CHAIR

Central Study Contacts

Vasiliki Mallikourti, PhD

CONTACT

+44 1224 437831; vasiliki.mallikourti@abdn.ac.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 19, 2026
• First Posted: March 25, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: March 25, 2026

Record last verified: 2026-03

Locations

GB (1)